These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16984333)

  • 1. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.
    Mehrotra DV; Li X; Gilbert PB
    Biometrics; 2006 Sep; 62(3):893-900. PubMed ID: 16984333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
    Gilbert PB; Sun Y
    Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chop-lump tests for vaccine trials.
    Follmann D; Fay MP; Proschan M
    Biometrics; 2009 Sep; 65(3):885-93. PubMed ID: 19210727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
    Gilbert PB; Self SG; Ashby MA
    Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the analysis of viral load endpoints in HIV vaccine trials.
    Hudgens MG; Hoering A; Self SG
    Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
    Wick WD
    Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data.
    Mogg R; Mehrotra DV
    Stat Med; 2007 Feb; 26(3):484-97. PubMed ID: 16625520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
    Gilbert PB; Bosch RJ; Hudgens MG
    Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.
    Cai T; Gilbert PB; Self SG
    J Biopharm Stat; 2006; 16(4):517-38. PubMed ID: 16892911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
    Gilbert PB; McKeague IW; Sun Y
    Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of methods to analyse continuous data from pseudo cluster randomized trials.
    Teerenstra S; Moerbeek M; Melis RJ; Borm GF
    Stat Med; 2007 Sep; 26(22):4100-15. PubMed ID: 17328006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive designs based on the truncated product method.
    Neuhäuser M; Bretz F
    BMC Med Res Methodol; 2005 Sep; 5():30. PubMed ID: 16171518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A control-conditional test for assessing HIV vaccine efficacy in small sample preclinical studies.
    Albert JM
    Stat Med; 1996 Nov 15-30; 15(21-22):2371-8; discussion 2405-12. PubMed ID: 8931207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.
    WHO/UNAIDS/IAVI International Expert Group
    AIDS; 2007 Feb; 21(4):539-46. PubMed ID: 17301582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of predictive markers of HIV disease progression in vaccine trials.
    Gurunathan S; Habib RE; Baglyos L; Meric C; Plotkin S; Dodet B; Corey L; Tartaglia J
    Vaccine; 2009 Mar; 27(14):1997-2015. PubMed ID: 19200450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV/AIDS research. Surprising AIDS vaccine success praised and pondered.
    Cohen J
    Science; 2009 Oct; 326(5949):26-7. PubMed ID: 19797628
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.